PhD in LNP Gene Therapy for Leukodystrophies

SIGRA; Amsterdam; On-site; EUR 30,000 - 42,000; Full time

Benefits offered by this job

Salary and mobility allowance

Network-wide training and secondments

International collaboration

Job summary

University College London (UCL) invites applications for a POLARIS doctoral PhD position embedded in the POLARIS consortium. You will focus on in vitro and in vivo preclinical assessment of genetic therapies for leukodystrophies, using lipid nanoparticle–based delivery of mRNA across cellular and animal models.

You will rotate through translational research stages, with supervision from UCL and secondments to gain exposure to patient organizations and additional disease models.

Qualifications

• Master's degree in life sciences with relevant research experience.
• Experience with molecular technologies, neuroscience and in vivo mouse studies.
• Interest in translational neuroscience and genetic therapies; LNPs experience is a plus.

Responsibilities

• Test LNP-mRNA delivery systems in vitro and in vivo in preclinical models.
• Analyse biodistribution and cellular tropism in brain and peripheral tissues.
• Conduct preclinical studies to evaluate therapeutic efficacy in leukodystrophy models.
• Collaborate with translational supervisors and POLARIS partners to advance clinical translation.

Skills

Molecular technologies

Neuroscience

In vivo mouse studies

Translational neuroscience

Interdisciplinary collaboration

Education

Master's degree in life sciences

Tools

Lipid nanoparticles (LNPs)

Nucleic acid delivery

Job description

University College London (UCL) invites applications for a POLARIS doctoral PhD position embedded in the POLARIS consortium. You will focus on in vitro and in vivo preclinical assessment of genetic therapies for leukodystrophies, using lipid nanoparticle–based delivery of mRNA across cellular and animal models.

You will rotate through translational research stages, with supervision from UCL and secondments to gain exposure to patient organizations and additional disease models.